EXICURE, INC. Stock Issued During Period, Value, Issued for Services
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- EXICURE, INC. stock issued during period, value, issued for services for the quarter ending 2018-12-31 was $0.00.
- EXICURE, INC. stock issued during period, value, issued for services for fiscal 2025 was $500.00K.
- EXICURE, INC. stock issued during period, value, issued for services for fiscal 2018 was $436.00K.
| Period end | Stock Issued During Period, Value, Issued for Services 3 month | Stock Issued During Period, Value, Issued for Services 12 month |
|---|---|---|
| 2025-12-31 | $500.00K 10-K · filed 2026-03-25 | |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-10 | $436.00K 10-K · filed 2020-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |